Composition comprising hyaluronic acid and mepivacaine
US10413637B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Feb 22, 2019 |
| Grant date | Sep 17, 2019 |
| Priority date | — |
| Expiry date | Feb 22, 2039 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61L2400/06
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A sterile composition for intraepidermal, intradermal, and/or subcutaneous administration including an effective amount of hyaluronic acid or a salt thereof, the effective amount of hyaluronic acid or salt thereof ranging from 1 to 3 wt % of the overall weight of the sterile composition, mepivacaine or a salt thereof as a first anesthetic agent at a concentration ranging from 0.05 to 3 wt % of an overall weight of the sterile composition, and a balanced salt solution in which the sterile composition exhibits greater stability over time and/or during heat treatment resulting in sterilization in comparison to the same composition having lidocaine as the anesthetic agent instead of mepivacaine.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.